Surface Logix Achieves Objectives With SLx-4090 in Phase 2a Clin...(nown as chylomicrons in enterocytes ther...)

Date:1/29/2008

nown as chylomicrons in enterocytes, thereby reducing the uptake of triglycerides and cholesterol into the lymphatic circulation and ultimately, the systemic circulation. Designed to exert its effect only in enterocytes, SLx-4090 avoids mechanistic toxicities in the liver (where MTP inhibition causes fatty liver) and other organs. MTP inhibitors that have been brought into development by others lack this critical feature and have therefore encountered significant toxicity concerns in the clinic, which will severely limit their therapeutic potential. SLx-4090 has potential not only in dyslipidemia but also in obesity as a result of the compound's ability to restrict caloric absorption by reducing the uptake of triglycerides. An excellent safety profile is paramount in both indications.

"The industry generally considers the intestine a barrier through which to drive compounds into the systemic circulation - that is, as an obstacle to be overcome," commented Dr. Paul Sweetnam, Chief Scientific Officer of Surface Logix. "In the case of MTP inhibition, Surface Logix viewed the gastrointestinal tract not as an obstacle, but as an ally in our quest for a viable therapeutic. By applying our expertise in the biophysics of small molecule-lipid and interfacial interactions through the use of our Pharmacomer(TM) Technology Platform, we were able to design a compound that takes advantage of these interactions. SLx-4090 effectively eliminates the major stumbling block of systemic bioavailability encountered by other MTP inhibitors and therefore offers tremendous commercial potential."

The results from the trial provide further confirmation of the ability of the Pharmacomer(TM) Technology Platform to enable Surface Logix scientists to design specific pharmacokinetic performance into a molecule while optimizing potency and selectivity. Surface Logix endowed SLx-4090 with its unique enterocyte-targeting nature in order to differentiate it from conventional systemically
'/>"/>

SOURCE Surface Logix, Inc. Copyright©2008 PR Newswire. All rights reserved

1 GOOD

Page: 1 2 3 4
Related biology technology :

1. Decision Biomarkers Awarded U.S. Patent for Protein Array Surface Chemistry
2. Sureshield Coatings Company Established to Market Industry-Leading Portfolio of Advanced Coatings for Metal Surfaces
3. Hill-Rom Introduces New Wound Therapy Surface With Innovative Safety and Treatment Features
4. Physicists pin down spin of surface atoms
5. NanoLogixs Hydrogen-From-Waste Technology at Welchs Foods Featured on Environmental Radio Program
6. NanoLogix, Inc. Makes Stock Pick List
7. FDA Grants Resverlogix Approval to Commence a Phase 1 Clinical Trial for RVX-208
8. Resverlogix Honoured with World Economic Forum Technology Pioneer Award
9. ForceLogix, Innovex Win Sales Operational Performance Award
10. NanoLogix Inc. Sets Date for Annual Shareholder Meeting and Provides Shareholder Update
11. Resverlogix is Presenting at IAS HDL Workshop